Trial record 1 of 5 for:    certolizumab pegol and psoriatic arthritis
Previous Study | Return to List | Next Study

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB BIOSCIENCES GmbH )
ClinicalTrials.gov Identifier:
NCT01087788
First received: March 15, 2010
Last updated: July 31, 2014
Last verified: July 2014
  Purpose

Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in subjects with adult onset active and progressive Psoriatic Arthritis (PsA).


Condition Intervention Phase
Arthritis, Psoriatic
Biological: CZP 200 mg Q2W
Biological: CZP 400 mg Q4W
Other: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)

Resource links provided by NLM:


Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • American College of Rheumatology 20 (ACR20) Response at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    ACR20 responders are those subjects with at least 20 % improvement from Baseline for Tender Joint Count (TJC), Swollen Joint Count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS).

  • Change From Baseline in Modified Total Sharp Score (mTSS) in Modification for Psoriatic Arthritis at Week 24 [ Time Frame: From Baseline to Week 24 ] [ Designated as safety issue: No ]

    Van der Heijde modified Total Sharp Score (mTSS) is a methodology to assess the degree of joint damage by quantifying the extent of bone erosions and joint space narrowing for 64 and 52 joints, respectively, with higher scores representing greater damage. mTSS (bone erosions) ranges from 0 (best possible outcome) to 320 (worst possible outcome); mTSS (joint space narrowing) ranges from 0 (best possible outcome) to 208 (worst possible outcome); and total score ranges from 0 (best possible outcome) to 528 (worst possible outcome).

    For the pre-defined analysis of this outcome measure, 0 was used for Baseline and the maximum observed mTSS value was used for Week 24 for those subjects which had less than 2 radiographs.

    The re-analysis is restricted to those subjects in the Randomized Set who have at least 2 x-ray values at scheduled visits, which are at least 8 weeks apart.



Secondary Outcome Measures:
  • American College of Rheumatology 20 (ACR20) Response at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    ACR20 responders are those subjects with at least 20 % improvement from Baseline for Tender Joint Count (TJC), Swollen Joint Count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS).

  • Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 24 [ Time Frame: From Baseline to Week 24 ] [ Designated as safety issue: No ]
    The HAQ-DI is a measure of function in Arthritis. There are 20 items in eight categories that represent a comprehensive set of functional activities on a scale from 0 (without difficulty) to 3 (unable to perform without assistance). The category scores are averaged into an overall HAQ-DI from 0 to 3. Scores of 0 to 1 generally represent mild to moderate difficulty, 1 to 2 represent moderate to severe disability, and 2 to 3 indicate severe to very severe disability. A negative value in HAQ-DI change from Baseline indicates an improvement from Baseline. The higher the negative value, the higher the improvement.

  • Psoriasis Area Severity Index (PASI75) Response at Week 24 in the Subgroup of Subjects With Psoriasis (PSO) Involving at Least 3 % Body Surface Area (BSA) at Baseline [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    The PASI75 response assessments are based on at least 75 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement.

  • Change From Baseline in Modified Total Sharp Score (mTSS) at Week 48 [ Time Frame: From Baseline to Week 48 ] [ Designated as safety issue: No ]

    Van der Heijde modified Total Sharp Score (mTSS) is a methodology to assess the degree of joint damage by quantifying the extent of bone erosions and joint space narrowing for 64 and 52 joints, respectively, with higher scores representing greater damage. mTSS (bone erosions) ranges from 0 (best possible outcome) to 320 (worst possible outcome); mTSS (joint space narrowing) ranges from 0 (best possible outcome) to 208 (worst possible outcome); and total score ranges from 0 (best possible outcome) to 528 (worst possible outcome).

    For the analysis of this outcome measure, the change from Baseline to Week 48 was imputed using the median change from Baseline among all subjects for those subjects, which had less than 2 radiographs.

    The post-hoc analysis presented here is based on the subgroup of subjects which had a Baseline mTSS value greater than 6.



Enrollment: 409
Study Start Date: March 2010
Estimated Study Completion Date: August 2015
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CZP 200 mg Q2W

Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.

At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.

Biological: CZP 200 mg Q2W
200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
Other Names:
  • Cimzia
  • Certolizumab Pegol
Other: Placebo
Matching Placebo to CZP injection.
Experimental: CZP 400 mg Q4W

Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.

Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind.

Biological: CZP 400 mg Q4W
400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
Other Names:
  • Cimzia
  • Certolizumab Pegol
Other: Placebo
Matching Placebo to CZP injection.
Placebo Comparator: Placebo

Matching Placebo to Certolizumab Pegol (CZP) injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group and were re-randomized to either CZP 200 mg Q2W or CZP 400 mg Q4W arm on Week 16.

After 24 weeks, all subjects were re-randomized to active treatment with CZP 200 mg every two weeks (Q2W) or CZP 400 mg every four weeks (Q4W).

Other: Placebo
Matching Placebo to CZP injection.
Placebo to CZP 200 mg escape on Week 16
Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
Biological: CZP 200 mg Q2W
200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
Other Names:
  • Cimzia
  • Certolizumab Pegol
Other: Placebo
Matching Placebo to CZP injection.
Placebo to CZP 400 mg escape on Week 16
Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
Biological: CZP 400 mg Q4W
400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
Other Names:
  • Cimzia
  • Certolizumab Pegol
Other: Placebo
Matching Placebo to CZP injection.
Placebo to CZP 200 mg on Week 24
Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
Biological: CZP 200 mg Q2W
200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
Other Names:
  • Cimzia
  • Certolizumab Pegol
Other: Placebo
Matching Placebo to CZP injection.
Placebo to CZP 400 mg on Week 24
Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
Biological: CZP 400 mg Q4W
400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
Other Names:
  • Cimzia
  • Certolizumab Pegol
Other: Placebo
Matching Placebo to CZP injection.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of adult-onset Psoriatic Arthritis (PsA) of at least 6 months' duration as defined by the Classification Criteria for Psoriatic Arthritis (CASPAR criteria)
  • Active Psoriatic Skin Lesions or a documented history of Psoriasis
  • Active Arthritis with ≥ 3 tender joints at Screening and Baseline, ≥ 3 swollen joints at Screening and Baseline and fulfilling at least 1 of the following 2 criteria during the Screening Period:

    1. Erythrocyte Sedimentation Rate (ESR) (Westergren) ≥ 28 mm/hour
    2. C-reactive protein (CRP) > Upper Limit Normal (ULN)
  • Failure to 1 or more treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Exclusion Criteria:

  • Diagnosis of any other inflammatory Arthritis or known diagnosis of Fibromyalgia
  • Exposure to more than 1 Tumor Necrosis Factor α (TNFα) antagonist or to more than 2 previous biological response modifiers for PsA or Psoriasis
  • Any non-biological systemic treatment of Psoriasis; phototherapy; topical agents
  • History of chronic or recurrent infections
  • High risk of infection
  • Live vaccination within the 8 weeks prior to Baseline
  • Concurrent malignancy or a history of malignancy
  • Class III or IV congestive Heart Failure - New York Heart Association (NYHA)
  • Demyelinating disease of the central nervous system
  • Clinically significant laboratory abnormalities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01087788

  Hide Study Locations
Locations
United States, Alabama
961
Birmingham, Alabama, United States
953
Tuscaloosa, Alabama, United States
United States, Arizona
954
Peoria, Arizona, United States
971
Scottsdale, Arizona, United States
United States, California
966
Palm Desert, California, United States
952
San Diego, California, United States
United States, Florida
957
Aventura, Florida, United States
962
Fort Lauderdale, Florida, United States
959
Orange Park, Florida, United States
958
Vero Beach, Florida, United States
United States, Maryland
964
Hagerstown, Maryland, United States
United States, Michigan
960
Kalamazoo, Michigan, United States
United States, Minnesota
969
Eagan, Minnesota, United States
United States, Mississippi
984
Flowood, Mississippi, United States
United States, Missouri
965
Florissant, Missouri, United States
950
St. Louis, Missouri, United States
United States, New York
985
Brooklyn, New York, United States
United States, North Carolina
963
Asheville, North Carolina, United States
United States, Ohio
976
Cleveland, Ohio, United States
951
Middleburg Heights, Ohio, United States
United States, Oklahoma
970
Oklahoma City, Oklahoma, United States
United States, Oregon
982
Portland, Oregon, United States
United States, Pennsylvania
972
Duncansville, Pennsylvania, United States
United States, Texas
975
Dallas, Texas, United States
978
Houston, Texas, United States
967
San Antonio, Texas, United States
United States, Washington
968
Seattle, Washington, United States
Argentina
700
Buenos Aires, Argentina
704
Buenos Aires, Argentina
707
Ciudad Autonoma de Buenos Aires, Argentina
705
Cordoba, Argentina
706
Rosario, Argentina
710
San Juan, Argentina
702
San Miguel De Tucuman, Argentina
708
San Miguel de Tucuman, Argentina
Belgium
152
Gent, Belgium
151
Liege, Belgium
Brazil
750
Curitiba, Brazil
757
Goias, Brazil
761
Goiâna, Brazil
753
Porto Alegre, Brazil
Canada, British Columbia
907
Victoria, British Columbia, Canada
Canada, Newfoundland and Labrador
900
St. John's, Newfoundland and Labrador, Canada
Canada, Ontario
904
Toronto, Ontario, Canada
910
Windsor, Ontario, Canada
Canada, Quebec
905
Trois-Rivires, Quebec, Canada
Czech Republic
504
Brno, Czech Republic
501
Hlucin, Czech Republic
500
Pardubice, Czech Republic
502
Praha 2, Czech Republic
505
Terezin, Czech Republic
503
Zlin, Czech Republic
France
206
Montpellier, France
204
Paris, France
202
Tours, France
Germany
252
Bad Nauheim, Germany
258
Berlin, Germany
257
Berlin, Germany
262
Frankfurt, Germany
255
Freiburg, Germany
254
Hamburg, Germany
253
Leipzig, Germany
263
München, Germany
256
Ratingen, Germany
Hungary
303
Budapest, Hungary
304
Budapest, Hungary
302
Debrecen, Hungary
301
Gyula, Hungary
306
Miskolc, Hungary
300
Veszprém, Hungary
Ireland
100
Dublin 4, Ireland
Italy
352
Ancona, Italy
350
Pisa, Italy
Mexico
802
Cuernavaca, Mexico
803
Mexico D.F., Mexico
Poland
458
Bialystok, Poland
452
Dabrowka, Poland
455
Elblag, Poland
459
Gdansk, Poland
457
Krakow, Poland
450
Lublin, Poland
454
Poznan, Poland
453
Torun, Poland
462
Warszawa, Poland
456
Warszawa, Poland
Spain
555
Madrid, Spain
550
Mérida, Spain
552
Santiago de Compostela, Spain
553
Sevilla, Spain
United Kingdom
605
Barnsley, United Kingdom
602
London, United Kingdom
601
Salford, United Kingdom
Sponsors and Collaborators
UCB BIOSCIENCES GmbH
Investigators
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 UCB
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: UCB Pharma ( UCB BIOSCIENCES GmbH )
ClinicalTrials.gov Identifier: NCT01087788     History of Changes
Other Study ID Numbers: PsA001, 2009-011720-59
Study First Received: March 15, 2010
Results First Received: October 25, 2013
Last Updated: July 31, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Belgium: Federal Agency for Medicinal Products and Health Products
Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Paul-Ehrlich-Institut
Hungary: Research Ethics Medical Committee
Ireland: Irish Medicines Board
Italy: Ministry of Health
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Poland: The Central Register of Clinical Trials
Spain: Agencia Española de Medicamentos y Productos Sanitarios
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Brazil: National Health Surveillance Agency
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Mexico: Federal Commission for Sanitary Risks Protection

Keywords provided by UCB Pharma:
Certolizumab Pegol
Cimzia

Additional relevant MeSH terms:
Arthritis
Arthritis, Psoriatic
Certolizumab pegol
Bone Diseases
Joint Diseases
Musculoskeletal Diseases
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Spinal Diseases
Spondylarthritis
Spondylarthropathies
Spondylitis
Immunoglobulin Fab Fragments
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 20, 2014